The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88
The US patent covers Modi-1 – the first clinical candidate from Scancell’s Moditope immunotherapy platform.
It claims methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1.
Similar protection has already been granted in Europe, South Africa, and Australia, as well as acceptance for grant in China.
As for the European patent announced today, that relates to FG88, a monoclonal antibody directed to tumour associated glycans, which Scancell said further strengthens the commercial positioning of its monoclonal antibody development programme.
“We are pleased to have been granted these two important patents for our immunotherapy platforms in the United States and Europe,” said chief executive Cliff Holloway.
“This Moditope patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell’s work in identifying a new class of cancer vaccine.”
He added: “Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies.”